Radioiodine treatment for benign thyroid disorders: Results of a nationwide survey of UK endocrinologists

Clinical Endocrinology

Volumn 68, Issue 5, 2008, Pages 814-820

  Vaidya, Bijay ^a   Williams, Graham R ^b   Abraham, Prakash ^c   Pearce, Simon H S ^d  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIONAMIDE; THYROXINE;

ADULT; ARTICLE; CLINICAL PRACTICE; ENDOCRINE OPHTHALMOPATHY; GOITER; GRAVES DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SPECIALIST; NORMAL HUMAN; OBSERVATION; OSTEOPOROSIS; PRIORITY JOURNAL; QUESTIONNAIRE; THYROIDECTOMY; UNITED KINGDOM;

FEMALE; GOITER; GRAVES DISEASE; GREAT BRITAIN; HUMANS; IODINE RADIOISOTOPES; MALE; PROFESSIONAL PRACTICE; QUESTIONNAIRES; THYROID DISEASES;

EID: 42149098954     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03097.x     Document Type: Article

References (46)

1. Weetman, A.P. (2007) Radioiodine treatment for benign thyroid diseases. Clinical Endocrinology, 66, 757 764.
2. British National Formulary (2006) Radioiodine therapy for hyperthyroidism. Drug and Therapeutics Bulletin, 44, 44 48.
3. Bonnema, S.J., Bartalena, L., Toft, A.D. Hegedus, L. (2002) Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. European Journal of Endocrinology, 147, 1 11.
4. Hedley, A.J., Lazarus, J.H., McGhee, S.M., Jones, R.B., Sharp, P.F., Naven, L.M., Beardwell, C.G. Hall, R. (1992) Treatment of hyperthyroidism by radioactive iodine. Summary of a UK national survey prepared for the Royal College of Physicians Committee on Endocrinology and Diabetes. Journal of the Royal College of Physicians of London, 26, 348 351.
5. Lazarus, J.H. Clarke, S. (1997) Use of radioiodine in the management of hyperthyroidism in the UK: development of guidelines. Thyroid, 7, 229 231.
6. Royal College of Physicians (1995) Guidelines: The Use of Radioiodine in the Management of Hyperthyroidism. RCP, London.
7. Allahabadia, A., Daykin, J., Holder, R.L., Sheppard, M.C., Gough, S.C. Franklyn, J.A. (2000) Age and gender predict the outcome of treatment for Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 85, 1038 1042.
8. Allahabadia, A., Daykin, J., Sheppard, M.C., Gough, S.C. Franklyn, J.A. (2001) Radioiodine treatment of hyperthyroidism: prognostic factors for outcome. Journal of Clinical Endocrinology and Metabolism, 86, 3611 3617.
9. Ron, E., Doody, M.M., Becker, D.V., Brill, A.B., Curtis, R.E., Goldman, M.B., Harris, B.S. 3rd., Hoffman, D.A., McConahey, W.M., Maxon, H.R., Preston-Martin, S., Warshauer, M.E., Wong, F.L. Boice, J.D. Jr. 1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. Journal of the American Medical Association, 280, 347 355.
10. Hegedus, L. Bennedbaek, F.N. (1997) Radioiodine for non-toxic diffuse goitre. Lancet, 350, 409 410.
11. Glinoer, D., Hesch, D., Lagasse, R. Laurberg, P. (1987) The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinologica. Supplementum, 285, 3 23.
12. Solomon, B., Glinoer, D., Lagasse, R. Wartofsky, L. (1990) Current trends in the management of Graves' disease. Journal of Clinical Endocrinology and Metabolism, 70, 1518 1524.
13. Walsh, J.P. (2000) Management of Graves' disease in Australia. Australian and New Zealand Journal of Medicine, 30, 559 566.
14. Tominaga, T., Yokoyama, N., Nagataki, S., Cho, B.Y., Koh, C.S., Chen, J.L. Shi, Y. (1997) International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China. Thyroid, 7, 217 220.
15. Escobar-Jimenez, F., Fernandez-Soto, M.L., Luna-Lopez, V., Quesada-Charneco, M. Glinoer, D. (2000) Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years. Postgraduate Medical Journal, 76, 340 344.
16. Abraham-Nordling, M., Torring, O., Hamberger, B., Lundell, G., Tallstedt, L., Calissendorff, J. Wallin, G. (2005) Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid, 15, 1279 1286.
17. Patel, N.N., Abraham, P., Buscombe, J. Vanderpump, M.P. (2006) The cost effectiveness of treatment modalities for thyrotoxicosis in a U.K. center. Thyroid, 16, 593 598.
18. Peters, H., Fischer, C., Bogner, U., Reiners, C. Schleusener, H. (1995) Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. European Journal of Clinical Investigation, 25, 186 193.
19. Jarlov, A.E., Hegedus, L., Kristensen, L.O., Nygaard, B. Hansen, J.M. (1995) Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clinical Endocrinology, 43, 325 329.
20. Leslie, W.D., Ward, L., Salamon, E.A., Ludwig, S., Rowe, R.C. Cowden, E.A. (2003) A randomized comparison of radioiodine doses in Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 978 983.
21. Imseis, R.E., Vanmiddlesworth, L., Massie, J.D., Bush, A.J. Vanmiddlesworth, N.R. (1998) Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 83, 685 687.
22. Bonnema, S.J., Bennedbaek, F.N., Veje, A., Marving, J. Hegedus, L. (2004) Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism, 89, 4439 4444.
23. Tallstedt, L., Lundell, G., Torring, O., Wallin, G., Ljunggren, J.G., Blomgren, H. Taube, A. (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. New England Journal of Medicine, 326, 1733 1738.
24. Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M.L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M.P., Lepri, A., Rossi, G., Martino, E. Pinchera, A. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine, 338, 73 78.
25. Perros, P., Kendall-Taylor, P., Neoh, C., Frewin, S. Dickinson, J. (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 90, 5321 5323.
26. Gussekloo, J., van Exel, E., de Craen, A.J., Meinders, A.E., Frolich, M. Westendorp, R.G. (2004) Thyroid status, disability and cognitive function, and survival in old age. Journal of the American Medical Association, 292, 2591 2599.
27. Parle, J.V., Maisonneuve, P., Sheppard, M.C., Boyle, P. Franklyn, J.A. (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet, 358, 861 865.
28. Sawin, C.T., Geller, A., Wolf, P.A., Belanger, A.J., Baker, E., Bacharach, P., Wilson, P.W., Benjamin, E.J. D'Agostino, R.B. (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New England Journal of Medicine, 331, 1249 1252.
29. Cappola, A.R., Fried, L.P., Arnold, A.M., Danese, M.D., Kuller, L.H., Burke, G.L., Tracy, R.P. Ladenson, P.W. (2006) Thyroid status, cardiovascular risk, and mortality in older adults. Journal of the American Medical Association, 295, 1033 1041.
30. Auer, J., Scheibner, P., Mische, T., Langsteger, W., Eber, O. Eber, B. (2001) Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American Heart Journal, 142, 838 842.
31. Foldes, J., Tarjan, G., Szathmari, M., Varga, F., Krasznai, I. Horvath, C. (1993) Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clinical Endocrinology, 39, 521 527.
32. Bauer, D.C., Ettinger, B., Nevitt, M.C. Stone, K.L. (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine, 134, 561 568.
33. Mudde, A.H., Houben, A.J. Nieuwenhuijzen Kruseman, A.C. (1994) Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clinical Endocrinology, 41, 421 424.
34. Faber, J., Jensen, I.W., Petersen, L., Nygaard, B., Hegedus, L. Siersbaek-Nielsen, K. (1998) Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clinical Endocrinology, 48, 285 290.
35. Murphy, E. Williams, G.R. (2004) The thyroid and the skeleton. Clinical Endocrinology, 61, 285 298.
36. Surks, M.I., Ortiz, E., Daniels, G.H., Sawin, C.T., Col, N.F., Cobin, R.H., Franklyn, J.A., Hershman, J.M., Burman, K.D., Denke, M.A., Gorman, C., Cooper, R.S. Weissman, N.J. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Journal of the American Medical Association, 291, 228 238.
37. McDermott, M.T., Woodmansee, W.W., Haugen, B.R., Smart, A. Ridgway, E.C. (2003) The management of subclinical hyperthyroidism by thyroid specialists. Thyroid, 13, 1133 1139.
38. Bonnema, S.J., Bennedbaek, F.N., Wiersinga, W.M. Hegedus, L. (2000) Management of the nontoxic multinodular goitre: a European questionnaire study. Clinical Endocrinology, 53, 5 12.
39. Diehl, L.A., Garcia, V., Bonnema, S.J., Hegedus, L., Albino, C.C. Graf, H. (2005) Management of the nontoxic multinodular goiter in Latin America: comparison with North America and Europe, an electronic survey. Journal of Clinical Endocrinology and Metabolism, 90, 117 123.
40. Bonnema, S.J., Bennedbaek, F.N., Ladenson, P.W. Hegedus, L. (2002) Management of the nontoxic multinodular goiter: a North American survey. Journal of Clinical Endocrinology and Metabolism, 87, 112 117.
41. Bhagat, M.C., Dhaliwal, S.S., Bonnema, S.J., Hegedus, L. Walsh, J.P. (2003) Differences between endocrine surgeons and endocrinologists in the management of non-toxic multinodular goitre. British Journal of Surgery, 90, 1103 1112.
42. Hegedus, L., Hansen, B.M., Knudsen, N. Hansen, J.M. (1988) Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. British Medical Journal, 297, 661 662.
43. Nygaard, B., Hegedus, L., Gervil, M., Hjalgrim, H., Soe-Jensen, P. Hansen, J.M. (1993) Radioiodine treatment of multinodular non-toxic goitre. British Medical Journal, 307, 828 832.
44. Nygaard, B., Hegedus, L., Ulriksen, P., Nielsen, K.G. Hansen, J.M. (1999) Radioiodine therapy for multinodular toxic goiter. Archives of Internal Medicine, 159, 1364 1368.
45. Nielsen, V.E., Bonnema, S.J., Boel-Jorgensen, H., Grupe, P. Hegedus, L. (2006) Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Archives of Internal Medicine, 166, 1476 1482.
46. Royal College of Physicians (2007) Radioiodine in the management of benign thyroid disease: clinical guidelines. Report of a Working Party. RCP, London.